Isocitrate Dehydrogenase Mutation and Risk of Venous Thromboembolism in Glioma: A Meta-Analysis

• DOI: 10.2139/ssrn.4146195
• Publication Date: 2022-07-17T14:37:26Z
• Authors: Soon Khai Low; Zauraiz Anjum; Amir Mahmoud; Utsav Joshi; Peter Kouides
• Keywords: Isocitrate dehydrogenase

Background: Patients with malignancies including malignant gliomas have a relatively high risk for venous thromboembolism (VTE). Recent evidence has linked isocitrate dehydrogenase (IDH) mutation reduced VTE in glioma patients. This meta-analysis aims to quantify the association of IDH status risks patients.Methods: We searched PubMed, Google Scholar, Medline OVID, Cochrane library, Cumulative Index Nursing and Allied Health Literature databases identify relevant studies. The overall odd ratio (OR) was pooled using random-effects model. evaluated statistical heterogeneity Cochran's Q statistics I2 tests. performed subgroup analyses according age, tumor, study design, quality.Results: A total 2600 patients from 8 studies were included meta-analysis. OR 0.21 (95% confidence interval [CI]: 0.09-0.46, I2=34%) mutant-type when compared wild-type gliomas. Among high-grade (III IV) patients, events IDH-mutant occurred an 0.28 CI: 0.14-0.53). No statistically significant decrease observed grade II gliomas, as indicated by 0.60 0.17-2.11).Conclusion: is significantly associated 72% lower among wild-type. Our findings suggest potential utility regarding thromboprophylaxis, need further elucidate association.